This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: NewAmsterdam Pharma Company (NAMS), Zoetis (ZTS)

Tipranks - Tipranks - Fri May 8, 12:12PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS), Zoetis (ZTS) and Charles River Labs (CRL) with bullish sentiments.

Claim 55% Off TipRanks

NewAmsterdam Pharma Company (NAMS)

In a report released today, Matt Phipps from William Blair maintained a Buy rating on NewAmsterdam Pharma Company. The company’s shares closed last Thursday at $33.06.

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 4.3% and a 44.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Bristol-Myers Squibb, and Compass Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $49.00 average price target, which is a 48.3% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $47.00 price target.

See today’s best-performing stocks on TipRanks >>

Zoetis (ZTS)

William Blair analyst Brandon Vazquez maintained a Buy rating on Zoetis today. The company’s shares closed last Thursday at $87.93.

According to TipRanks.com, Vazquez is ranked 0 out of 5 stars with an average return of -5.3% and a 30.2% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Edwards Lifesciences, and Irhythm Technologies. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zoetis with a $147.20 average price target, representing a 62.4% upside. In a report released yesterday, TipRanks – xAI also upgraded the stock to Buy with a $127.00 price target.

Charles River Labs (CRL)

In a report released today, Max Smock from William Blair reiterated a Buy rating on Charles River Labs. The company’s shares closed last Thursday at $186.00.

According to TipRanks.com, Smock is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.1% and a 19.4% success rate. Smock covers the Healthcare sector, focusing on stocks such as Fortrea Holdings Inc., Lifecore Biomedical, and Medpace Holdings. ;'>

Currently, the analyst consensus on Charles River Labs is a Moderate Buy with an average price target of $197.30.

Read More on NAMS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).